DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes
dc.contributor.author | Kizhakeyil, Atish | |
dc.contributor.author | Zaini, Nurmahirah Binte Mohammed | |
dc.contributor.author | Poh, Zhi Sheng | |
dc.contributor.author | Wong, Brandon Han Siang | |
dc.contributor.author | Loh, Xinpeng | |
dc.contributor.author | Ng, Aik Seng | |
dc.contributor.author | Low, Zun Siong | |
dc.contributor.author | Prasannan, Praseetha | |
dc.contributor.author | Gong, Chun | |
dc.contributor.author | Tan, Michelle Guet Khim | |
dc.contributor.author | Nagarajan, Chandramouli | |
dc.contributor.author | Huang, Dachuan | |
dc.contributor.author | Lu, Pang Wan | |
dc.contributor.author | Lim, Jing Quan | |
dc.contributor.author | Barrans, Sharon | |
dc.contributor.author | Ong, Choon Kiat | |
dc.contributor.author | Lim, Soon Thye | |
dc.contributor.author | Chng, Wee Joo | |
dc.contributor.author | Follows, George | |
dc.contributor.author | Hodson, Daniel J. | |
dc.contributor.author | Du, Ming Qing | |
dc.contributor.author | Goh, Yeow Tee | |
dc.contributor.author | Tan, Suat Hoon | |
dc.contributor.author | Grigoropoulos, Nicholas Francis | |
dc.contributor.author | Verma, Navin Kumar | |
dc.date.accessioned | 2021-10-18T08:50:19Z | |
dc.date.available | 2021-10-18T08:50:19Z | |
dc.date.issued | 2021-10-16 | |
dc.date.submitted | 2021-07-27 | |
dc.identifier.other | s12943-021-01437-0 | |
dc.identifier.other | 1437 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/329546 | |
dc.description | Funder: addenbrooke's charitable trust, cambridge university hospitals; doi: http://dx.doi.org/10.13039/501100002927 | |
dc.language | en | |
dc.publisher | BioMed Central | |
dc.subject | Letter to the Editor | |
dc.subject | DDX3X mutation | |
dc.subject | Hematolymphoid malignancy | |
dc.subject | Prognosis | |
dc.subject | Tumour metastasis | |
dc.subject | Drug resistance | |
dc.title | DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes | |
dc.type | Other | |
dc.date.updated | 2021-10-18T08:50:18Z | |
prism.issueIdentifier | 1 | |
prism.publicationName | Molecular Cancer | |
prism.volume | 20 | |
dc.identifier.doi | 10.17863/CAM.76994 | |
dcterms.dateAccepted | 2021-09-24 | |
rioxxterms.versionofrecord | 10.1186/s12943-021-01437-0 | |
rioxxterms.version | VoR | |
rioxxterms.licenseref.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.contributor.orcid | Verma, Navin Kumar [0000-0002-5940-6633] | |
dc.identifier.eissn | 1476-4598 | |
pubs.funder-project-id | nanyang technological university (L0412290) | |
pubs.funder-project-id | ministry of education - singapore (MOE2017-T2-2-004) | |
pubs.funder-project-id | national medical research council (OFLCG18May-0028, NMRC/TA/0051/2016) | |
pubs.funder-project-id | kay kendall leukaemia fund (KKL649) | |
pubs.funder-project-id | medical research council (MR/M008584/1) | |
pubs.funder-project-id | wellcome trust (203151/Z/16/Z) | |
pubs.funder-project-id | cancer research uk (A25117) |
Files in this item
This item appears in the following Collection(s)
-
Jisc Publications Router
This collection holds Cambridge publications received from the Jisc Publications Router